Latest News
Aquestive Therapeutics, Inc.
- Form 4 Aquestive Therapeutics Inc: John Cochran (Director) For: 21 October
- Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton Pharmaceuticals
- AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST)
- Aquestive Therapeutics moves R&D to HELIX in New Brunswick
- Aquestive Therapeutics shifts R&D to The HELIX in New Brunswick
- FDA Accepts Aquestive Therapeutics’ Anaphylm Application for Review
- Aquestive Therapeutics Announces FDA Acceptance of
- Legal probe launched over alleged false claims on Aquestive's drug Anaphylm and FDA delays.
- Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's Success (NASDAQ:AQST)
- Aquestive Therapeutics elects Richard J. Daly to its Board as Class I director
- Form 8K Aquestive Therapeutics Inc For: 29 September By Investing.com
- Aquestive Therapeutics posts investor presentation; NDA resubmission for Anaphylm, $98.5M cash
Headlines from the last 30 days, linking to the original publishers. See all market news →